As of November 10, 2020
Considering the management performance and financial condition overall, Takara Bio recognizes a basic policy aimed for profit contribution, positioning the profit distribution to shareholders as an important issue for management as well as enhancing the internal reserves to strengthen the R&D activities of three business segments: Bioindustry, Gene Therapy, and AgriBio businesses.
Specifically, our policy calls for a target rate of around 20% of estimated profit calculated without considering extraordinary income or loss in the consolidated financial statements.
| FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 （Expected） |
||
|---|---|---|---|---|---|---|---|
| Dividend Per Share(yen) | 1Q | - | - | - | - | - | - |
| 2Q | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 3Q | - | - | - | - | - | - | |
| FY-End | 4.50 | 7.00 | 8.00 | 16.00 | 33.00 | 33.00 | |
| Total | 4.50 | 7.00 | 8.00 | 16.00 | 33.00 | 33.00 | |
| Amount of Dividends(million yen) | 541 | 842 | 963 | 1,926 | 3,973 | - | |
| Payout Ratio(%) | 23.2 | 23.0 | 25.2 | 20.2 | 20.0 | 37.5 | |
| Ratio of Total Amount of Dividends to Net Assets(%) | 0.9 | 1.3 | 1.5 | 2.7 | 4.7 | - | |
We have not bought back our shares as of today.